Curanex net loss widens to $3.29 million in Q2 FY26; no revenue

• Curanex posted a net loss of $3.29 million for the quarter ended June 30, 2026, versus a $60,346 loss a year earlier.
• No revenue was reported; R&D expense climbed to $2.59 million from $57,658, driven by IND-related study spending.
• General and administrative costs rose to $731,843 from $57,658, reflecting higher payroll and public-company professional fees.
• Cash and cash equivalents fell to $2.94 million at June 30 from $4.97 million at Dec. 31; operating cash outflow was $2.03 million.
• Program updates included a February GMP pilot-scale Phyto-N batch, March dose-range toxicology completion, and an ulcerative colitis IND targeted for Q4 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Curanex Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-038145), on August 14, 2026, and is solely responsible for the information contained therein.